Uptake of bone-modifying agents in patients with HER2+ metastatic breast cancer with bone metastases - prospective data from a multi-site Australian registry.
bone health
bone metastases
bone-modifying agents
breast cancer
oncology
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
15
04
2021
received:
20
01
2021
accepted:
22
04
2021
pubmed:
19
5
2021
medline:
25
10
2022
entrez:
18
5
2021
Statut:
ppublish
Résumé
International practice guidelines recommend administration of bone-modifying agents (BMA) in metastatic breast cancer (MBC) patients with bone metastases to reduce skeletal-related events (SRE). Optimal delivery of BMA in routine clinical practice, including agent selection and prescribing intervals, remains unclear. To describe real-world practice of Australian breast oncologists. Prospective data from February 2015 to July 2020 on BMA delivery to MBC patients with bone metastases was analysed from Treatment of Advanced Breast Cancer in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Australian Patient (TABITHA), a multi-site Australian HER2+ MBC registry. Of 333 HER2+ MBC patients, 171 (51%) had bone metastases at diagnosis, with a mean age of 58.1 years (range, 32-87). One hundred and thirty (76%) patients received a BMA, with 90 (69%) receiving denosumab and 40 (31%) receiving a bisphosphonate. Patients who received a BMA were more likely to have received concurrent first-line systemic anti-HER2 therapy (95% vs 83%; P = 0.04), to present with bone-only metastases at diagnosis (24% vs 7%; P = 0.02) and less likely to have visceral metastases (51% vs 71%; P = 0.03). Ten of 40 (25%) bisphosphonate patients and 45 of 90 (50%) denosumab patients received their BMA at the recommended 4-weekly interval. Prescribing intervals varied over time. Adverse events reported were consistent with clinical trial data. Three-quarters of Australian HER2+ MBC patients with bone metastases receive a BMA, often at different schedules than guidelines recommend. Further studies, including all MBC subtypes, are warranted to better understand clinicians' prescribing rationale and potential consequences of current prescribing practice on SRE incidence.
Sections du résumé
BACKGROUND
International practice guidelines recommend administration of bone-modifying agents (BMA) in metastatic breast cancer (MBC) patients with bone metastases to reduce skeletal-related events (SRE). Optimal delivery of BMA in routine clinical practice, including agent selection and prescribing intervals, remains unclear.
AIM
To describe real-world practice of Australian breast oncologists.
METHODS
Prospective data from February 2015 to July 2020 on BMA delivery to MBC patients with bone metastases was analysed from Treatment of Advanced Breast Cancer in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Australian Patient (TABITHA), a multi-site Australian HER2+ MBC registry.
RESULTS
Of 333 HER2+ MBC patients, 171 (51%) had bone metastases at diagnosis, with a mean age of 58.1 years (range, 32-87). One hundred and thirty (76%) patients received a BMA, with 90 (69%) receiving denosumab and 40 (31%) receiving a bisphosphonate. Patients who received a BMA were more likely to have received concurrent first-line systemic anti-HER2 therapy (95% vs 83%; P = 0.04), to present with bone-only metastases at diagnosis (24% vs 7%; P = 0.02) and less likely to have visceral metastases (51% vs 71%; P = 0.03). Ten of 40 (25%) bisphosphonate patients and 45 of 90 (50%) denosumab patients received their BMA at the recommended 4-weekly interval. Prescribing intervals varied over time. Adverse events reported were consistent with clinical trial data.
CONCLUSION
Three-quarters of Australian HER2+ MBC patients with bone metastases receive a BMA, often at different schedules than guidelines recommend. Further studies, including all MBC subtypes, are warranted to better understand clinicians' prescribing rationale and potential consequences of current prescribing practice on SRE incidence.
Substances chimiques
Denosumab
4EQZ6YO2HI
Receptor, ErbB-2
EC 2.7.10.1
Diphosphonates
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1707-1716Informations de copyright
© 2021 Royal Australasian College of Physicians.
Références
Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L et al. Bone metastases: an overview. Oncol Rev 2017; 11: 321.
Heeke A, Nunes MR, Lynce F. Bone-modifying agents in early-stage and advanced breast cancer. Curr Brast Cancer Rep 2018; 10: 241-50.
Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E et al. Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol 2020; 31: 1650-63.
Van Poznak CV, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ et al. Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline update. J Clin Oncol 2017; 35: 3978-86.
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andre F et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol 2018; 29: 1634-57.
Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; 48: 3082-92.
Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735-44.
Stopeck A, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132-9.
Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G et al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 2013; 14: 663-70.
Hortobagyi GN, Van Poznak CV, Harker WG, Gradishar WJ, Chew H, Dakhil SR et al. Continued treatment effect of Zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. JAMA Oncol 2017; 3: 906-12.
Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ et al. Effect of longer-interval vs standard dosing of Zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA 2017; 317: 48-58.
Awan A, Paterson A, Clemons M. De-escalation of bone-modifying agents in patients with bone metastases: the best of times and the worst of times? J Oncol Pract 2018; 14: 465-7.
Luo Q, Men P, Liu Z, Zhai S, Jiang M. Is de-escalated bisphosphonates therapy a suitable alternative to standard dosing in malignant tumour patients with bone metastases: a systematic review and meta-analysis. Front Oncol 2019; 9: 774.
Narayanan P. Denosumab: a comprehensive review. South Asian J Cancer 2017; 2: 272-7.
Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008; 14: 6690-6.
Fizazi K, Lipton A, Mariette X, Body JJ, Rashim Y, Gralow JR et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27: 1564-71.
McGrath LJ, Overman RA, Reams D, Cetin K, Liede A, Narod SA et al. Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US. Clin Epidemiol 2018; 10: 1349-58.
Schröder J, Fietz T, Köhler A, Peterson V, Tesch H, Spring L et al. Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer - results from the prospective German Tumour Registry Breast Cancer cohort study. Eur J Cancer 2017; 79: 139-48.
Arican A, Bozhurt T, Bozcuk H, Demirkan B, Buyukberber S, Alkis N et al. A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey. Support Care Cancer 2014; 22: 2629-34.
Kuchuk I, Hutton B, Moretto P, Ng T, Addison CL, Clemons M. Incidence, consequences and treatment of bone metastases in breast cancer patients-experience from a single cancer Centre. J Bone Oncol 2013; 2: 137-44.
Murphy L, McCarthy J, McCrate F, Laing K, Powell E, Seal M et al. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre. Support Care Cancer 2013; 21: 1557-60.
Giordano SH, Fang S, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS et al. Use of intravenous bisphosphonates in older women with breast cancer. Oncologist 2008; 13: 494-502.
Body JJ, von Moos R, Rider A, Hallworth P, Bhowmik D, Gatta F et al. A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe. J Bone Oncol 2018; 14: 100212.
Marr HK, Stiles CR, Boyar MA, Braun TC, Hagen NA, Janzen C et al. Feasibility of administering zoledronic acid in palliative patients being cared for in the community: results of a pilot study. Curr Oncol 2010; 17: 69-74.
Porta-Sales J, Garzón-Rodríguez C, Llorens-Torromé S, Brunelli C, Pigni A, Caraceni A. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: a systematic review within the European Association for Palliative Care guidelines project. Palliat Med 2017; 31: 5-25.
Yoong J, Poon P. Principles of cancer pain management: an overview and focus on pharmacological and interventional strategies. Aust J Gen Pract 2018; 47: 758-62.
von Moos R, Body JJ, Rider A, de Courcy J, Bhowmik D, Gatta F et al. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries. J Bone Oncol 2017; 11: 1-9.
O'Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2017; 10: CD003474.
D'Oronzo S, Coleman R, Brown J, Silvestris F. Metastatic bone disease: pathogenesis and therapeutic options. J Bone Oncol 2018; 15: 4.
McGrath LJ, Hernandez RK, Overman R, Reams D, Liede A, Brookhart MA et al. Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States. Cancer Med 2019; 8: 374-82.
AlZahrani M, Clemons M, Vandermeer L, Sienkiewicz M, Awan AA, Hutton B et al. Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: a physician survey. J Bone Oncol 2020; 26: 100339.
Mark M, Thürlimann B, Ribi K, Schär C, Dietrich D, Cathomas R et al. Patterns of care for patients with metastatic bone disease in solid tumors: a cross-sectional study from Switzerland (SAKK 95/16). J Bone Oncol 2019; 21: 100273.
Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS et al. Cost-effectiveness analysis of monthly zoledronic acid, zoledronic acid every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases: CALGB 70604 (Alliance). J Clin Oncol 2017; 35: 3949-55.
Dranitsaris G, Hatzimichael E. Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients. Support Care Cancer 2012; 20: 1353-60.
Tella SH, Kommalapati A, Singhi RK. Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents. Transl Cancer Res 2018; 7: S81-4.
Clemons M, Ong M, Stober C, Ernst S, Booth C, Canil C et al. A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. Eur J Cancer 2021; 142: 132-40.
Anastasilakis A, Polyzos S, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 2017; 32: 1291-6.
Gonzalez-Rodriguez E, Aubry-Rozier B, Stoll D, Zaman K, Lamy O. Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors. Breast Cancer Res Treat 2019; 179: 153-9.
Lamy O, Stoll D, Aubry-Rozier B, Rodriguez E. Stopping Denosumab. Curr Osteoporos Rep 2019; 17: 8-15.
Gonzalez-Rodriguez E, Aubry-Rozier B, Stoll D, Zaman K, Lamy O. Increased risk of multiple spontaneous vertebral fractures at denosumab discontinuation must be taken into account. J Clin Oncol 2020; 38: 1641-2.
Mjelstad A, Zakariasson G, Valachis A. Optimizing antiresorptive treatment in patients with bone metastases: time to initiation, switching strategies, and treatment duration. Support Care Cancer 2019; 27: 3859-67.
Ng T, Tu M, Ibrahim M, Basulaiman BM, McGee S, Srikanthan A et al. Efficacy and toxicity of extending bone modifying agents beyond two years for bone metastases in breast or castrate-resistant prostate cancer patients: a systematic review. J Clin Oncol 2020; 38: e24083.